A study has shown that the ureido-sulfonamide CAIX inhibitor SLC-0111 in combination with anti-PD-1 and anti-CTLA4 increased the effector function of T-cells (granzyme B production), inhibited tumour growth, and reduced metastasis in the B16.F10 and 4T1 syngeneic tumour models [177]. This evidence concerns the gene GZMB and neoplasm.